ImmunityBio Appoints Fabio M. Benedetti, M.D., as Chief Strategy Officer

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, today announced that it has appointed Fabio M. Benedetti, M.D., as Chief Strategy Officer, effective January 4, 2021. Dr. Benedetti brings more than 20 years of biotech and large pharma experience in oncology clinical development and medical affairs. In this role, he will oversee life-cycle management, pipeline and commercial strategy, including medical affairs. Following the completion of ImmunityB

Click to view original post